Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 19:04:36·⟳ 抓取 19:05:03 +27s·⚡ 决策 10-21 19:09:06 +4m03s·6.1 天前
Roivant的brepocitinib在两项非感染性葡萄膜炎III期试验达到主要终点（Investing.com为AI改写稿，同一通稿已处理）
本条Investing.com报道是Roivant/Priovant公司通稿（GlobeNewswire wire，11:05 UTC已被本臂处理）的AI改写版，关键事实（双III期主要终点阳性、安全性、2027H1 sNDA）全部已在已处理记录中，且原始通稿还含HR与p值等更详细数据；本条无任何新增金额、指引修正或监管进展，属同一具体催化的重复信号，按查重规则不重复研判、不开新仓。
📄 原文Investing.com↗ 原文
Roivant’s brepocitinib meets primary endpoint in uveitis trials
SpaceX, Tesla shares rise after Musk says committees exploring possible merger BASEL, Switzerland/LONDON/NEW YORK/DURHA…
不做 Roivant Sciences（ROIV.US）
重复信号：CLARITY-1/2阳性的公司原始通稿已于2026-10-21 11:05 UTC被wire源处理，本条Investing.com报道为无新增事实的AI改写；盘前股价已+7%正在重定价，无独立edge，不重复开仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
brepocitinib葡萄膜炎双III期阳性是Roivant实质利好，但公司原始通稿已于2分钟前被处理，Investing.com此稿为无新增信息的AI改写；盘前ROIV已涨约7%正在重定价，重复信号不再追单。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 节点
- 节点
关键理由
- 同一催化的首发通稿已在11:05 UTC处理，本条仅为聚合站AI改写，不含增量事实
主要风险
- 若后续出现完整数据披露、分析师上调或合作方新信息等实质增量，应作为新事件重新研判而非沿用本条
先例如何影响了这次决策
对本次决策的影响:查重命中已处理的同一通稿，直接AVOID；不对涨幅/止盈止损做校准
方向:未做先例研究：本条在跨源查重阶段即确认为同一催化的无增量重复信号，按早停规则不再检索历史先例
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 4,015 ms
{"result": "search_processed_events:agent query=`lisraya snda uveitis 2027 | roiv priovant brepocitinib 葡萄膜炎 三期临床 | roivant brepocitinib phase 3 uveitis clarity-1 clarity-2 primary endpoint`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、22126 条本臂决策(完整)，返回 3 条候选。\n• 10-21 11:05 UTC(北京 19:05) [bm25:71%,ticker] - fetch_decision_experience 成功 stock_tools_inprocess · 7 ms
{ - stock_quote 成功 stock_tools HTTP · 486 ms
{ - web_search 成功 doubao_search · 1,465 ms
豆包搜索结果（原始查询:Roivant brepocitinib CLARITY-1 CLARITY-2 uveitis Phase 3 primary endpoint；API SearchType:web）
原文全文
展开原文 · 1,930 字
SpaceX, Tesla shares rise after Musk says committees exploring possible merger
BASEL, Switzerland/LONDON/NEW YORK/DURHAM, N.C. - Roivant Sciences (NASDAQ:ROIV) announced today that brepocitinib achieved the primary endpoint in two Phase 3 trials for non-infectious uveitis, according to a press release statement.
The CLARITY-1 and CLARITY-2 studies enrolled 371 patients who received either brepocitinib 45 mg once daily or placebo for 48 weeks. The primary endpoint measured time to treatment failure from Week 6 through Week 48.
Median time to treatment failure for brepocitinib patients exceeded 48 weeks in both studies, compared with approximately 12 weeks for placebo patients in each study. The cumulative incidence of treatment failure at Week 48 was 35.4% for brepocitinib versus 78.7% for placebo in CLARITY-1, and 32.4% versus 77.8% in CLARITY-2.
In pooled results, 62% of patients on brepocitinib achieved steroid-free quiescence at Week 48, compared with 20% on placebo. Among patients who entered the studies with macular edema, 42% of eyes on brepocitinib achieved resolution at Week 48, compared with 4.8% on placebo.
Brepocitinib was generally well tolerated, with 3% of participants discontinuing treatment due to adverse events. The safety profile was consistent with prior brepocitinib clinical trials, with no new safety signals observed.
Non-infectious uveitis affects an estimated 70,000 to 190,000 adults in the United States and is a leading cause of blindness among the working-age population.
Priovant Therapeutics, a Roivant subsidiary, plans to file a supplemental New Drug Application for brepocitinib for the treatment of non-infectious uveitis in the first half of 2027. Brepocitinib is currently approved under the brand name LISRAYA for treatment of dermatomyositis in adult patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BASEL, Switzerland/LONDON/NEW YORK/DURHAM, N.C. - Roivant Sciences (NASDAQ:ROIV) announced today that brepocitinib achieved the primary endpoint in two Phase 3 trials for non-infectious uveitis, according to a press release statement.
The CLARITY-1 and CLARITY-2 studies enrolled 371 patients who received either brepocitinib 45 mg once daily or placebo for 48 weeks. The primary endpoint measured time to treatment failure from Week 6 through Week 48.
Median time to treatment failure for brepocitinib patients exceeded 48 weeks in both studies, compared with approximately 12 weeks for placebo patients in each study. The cumulative incidence of treatment failure at Week 48 was 35.4% for brepocitinib versus 78.7% for placebo in CLARITY-1, and 32.4% versus 77.8% in CLARITY-2.
In pooled results, 62% of patients on brepocitinib achieved steroid-free quiescence at Week 48, compared with 20% on placebo. Among patients who entered the studies with macular edema, 42% of eyes on brepocitinib achieved resolution at Week 48, compared with 4.8% on placebo.
Brepocitinib was generally well tolerated, with 3% of participants discontinuing treatment due to adverse events. The safety profile was consistent with prior brepocitinib clinical trials, with no new safety signals observed.
Non-infectious uveitis affects an estimated 70,000 to 190,000 adults in the United States and is a leading cause of blindness among the working-age population.
Priovant Therapeutics, a Roivant subsidiary, plans to file a supplemental New Drug Application for brepocitinib for the treatment of non-infectious uveitis in the first half of 2027. Brepocitinib is currently approved under the brand name LISRAYA for treatment of dermatomyositis in adult patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
adf8b068fa· 2026-10-21 19:09 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前